SAN CARLOS, Calif., April 25 /PRNewswire/ -- Nuvelo, Inc. today announced that it will participate in the following events in May:
Deutsche Bank 32nd Annual Health Care Conference
May 3, 2007
9:45 a.m. ET
Ward Wolff, SVP, Finance and CFO http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NUVO&item_id=1527404
Brean Murray, Carret & Co. 2007 Small Cap Healthcare & Biotechnology One on One Conference
May 15, 2007
Dr. Michael Levy, EVP, Research and Development
First Quarter 2007 Financial Results and Accomplishments Conference Call & Webcast
May 9, 2007 4:30 p.m. ET (1:30 p.m. PT) Dr. Ted W. Love, Chairman and CEO Dr. Michael Levy, EVP, Research and Development Ward Wolff, SVP, Finance and CFO
Dial in: 800-299-9630 domestic and 617-786-2904 international with passcode 53818431
Replay: 888-286-8010 domestic and 617-801-6888 international with passcode 47035625, available through Wednesday, May 23, 2007
Webcast: www.nuvelo.com or visit the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.
2007 Annual Shareholders Meeting May 31, 2007 2:00 p.m. ET (11:00 a.m. PT) Sofitel San Francisco Bay 223 Twin Dolphin Drive, Redwood City, CA 94065
If you plan to attend, please RSVP at ir@nuvelo.com Webcast: www.nuvelo.com or visit the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.
Live audio webcasts of the events and presentations will also be available online via the Investor Relations portion of Nuvelo’s website at www.nuvelo.com.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rNAPc2 which is in Phase 2 testing for potential use as a cancer therapy, as well as NU206 a preclinical candidate for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.
CONTACT: Nicole Foderaro, Director, Corporate Communications & IR ofNuvelo, Inc., +1-650-517-8472, or nfoderaro@nuvelo.com
Web site: http://www.nuvelo.com//
